Kpv Peptide Buy

Sourcing Laboratory-Grade KPV Peptide for Research

When purchasing KPV for experimental protocols, investigators must ensure that the compound is synthesized under strict quality controls and verified by independent analytical testing. KPV is a C-terminal tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH), corresponding to the amino acid sequence Lysine-Proline-Valine. Research teams evaluating suppliers must prioritize high chemical purity, documented low endotoxin levels, and full batch traceability.

At PX1 Research, every batch of KPV tripeptide is manufactured in USA-based, GMP-compliant facilities and tested through an independent ISO 17025 accredited laboratory. Researchers looking to explore our broader catalog of research reagents can review our complete selection of all peptides for comparative study designs.

Molecular Structure and Biochemical Profile of KPV

KPV represents the carboxyl-terminal sequence (α-MSH 11–13) of the larger pro-opiomelanocortin (POMC)-derived peptide α-MSH. Despite lacking the complete amino acid sequence required for classical melanocortin receptor (MCR) activation, KPV retains potent biological signaling capabilities through non-receptor-mediated and transporter-assisted mechanisms.

The molecular formula of KPV is C16H30N4O4, with a molecular mass of approximately 342.43 g/mol. In vitro structural analyses demonstrate that the inclusion of the central proline residue imparts conformational rigidity, which helps preserve peptide stability against enzymatic cleavage by ambient peptidases. Preclinical models indicate that KPV enters intestinal epithelial cells via the oligopeptide transporter PepT1 (SLC15A1), allowing for intracellular signal modulation.

Mechanisms of Action in Inflammatory Signaling Pathways

Preclinical studies suggest that the primary biological mechanism of KPV involves the downregulation of nuclear factor kappa B (NF-κB) nuclear translocation. NF-κB functions as a primary transcriptional regulator of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and IL-8. By inhibiting the phosphorylation and degradation of IκB proteins, KPV prevents the activation of downstream inflammatory cascades.

In vitro data indicate that KPV also interacts directly with intracellular targets to suppress the activity of inflammatory cascades without triggering melanogenesis, a common feature of full-length melanocortin agonists like alpha-MSH. This selective anti-inflammatory profile makes KPV an ideal candidate for isolating pathway-specific cellular responses in cell culture assays and mucosal tissue models.

Preclinical Literature: Intestinal Barrier Integrity and Colitis Models

The scientific literature regarding KPV focuses extensively on its capacity to preserve intestinal barrier function and reduce mucosal inflammation. In animal models of dextran sulfate sodium (DSS)-induced and trinitrobenzene sulfonic acid (TNBS)-induced colitis, administration of KPV demonstrated significant reductions in histological inflammation scores, myeloperoxidase (MPO) activity, and mucosal ulceration.

Cellular assays using Caco-2 monolayers demonstrate that KPV attenuates cytokine-induced disruption of tight junction proteins, including zonula occludens-1 (ZO-1) and occludin. By maintaining epithelial tight junction architecture, KPV limits paracellular permeability and bacterial translocation, providing valuable insights into inflammatory bowel disease (IBD) pathogenesis within the PX1 Research library.

Antimicrobial and Anti-Infective Properties in Preclinical Research

Beyond its immunomodulatory capacity, preclinical research indicates that KPV possesses direct antimicrobial properties against pathogen strains such as *Candida albicans* and *Staphylococcus aureus*. Microdilution assays demonstrate that KPV inhibits germ tube formation and fungal hyphal outgrowth at micromolar concentrations.

The dual mechanism—combining direct pathogen inhibition with localized anti-inflammatory signaling—renders KPV a unique experimental tool for researching complex co-infections and chronic inflammatory conditions of mucosal surfaces.

Comparative Analysis: KPV vs. BPC-157 vs. LL-37 in Inflammatory Models

Researchers evaluating anti-inflammatory and tissue repair mechanisms often compare KPV against other prominent research compounds within mucosal and epithelial models. While KPV functions primarily via PepT1-mediated transport and NF-κB inhibition, BPC-157 operates through nitric oxide pathway modulation, VEGFR2 activation, and focal adhesion kinase stimulation to promote angiogenesis and tissue healing.

Conversely, the antimicrobial peptide LL-37 exerts direct membrane-disrupting bactericidal effects alongside chemoattractant signaling via FPRL1 receptors. Additionally, investigators studying systemic soft tissue recovery may incorporate TB-500 to examine actin sequestration and cell migration pathways alongside KPV's localized anti-inflammatory effects.

Evaluating Supplier Quality: Analytical Verification and COA Requirements

To ensure reproducible experimental outcomes, research teams must rigorously verify supplier quality parameters prior to procurement. Substandard peptides containing truncated sequences, residual TFA salts, or endotoxin contamination can confound cell culture assays and animal study data.

PX1 Research maintains an uncompromising quality assurance standard for every lot of KPV:

• Reverse-Phase HPLC (RP-HPLC): Confirms chemical purity exceeds 98.0%, eliminating truncated or modified synthesis side-products. • Mass Spectrometry (ESI-MS): Verifies exact molecular weight and structural identity. • Endotoxin Testing: LAL assay ensures endotoxin levels remain strictly below <0.01 EU/mg, preventing non-specific immune activation in primary cell assays. • Lyophilization & Atmosphere: Packaged in sealed, argon-purged glass vials to eliminate oxidation and moisture degradation. • USA Manufacturing: Synthesized under ISO 9001 and GMP-compliant operational standards.

Reconstitution Protocol and In Vitro Handling Guidelines

Lyophilized KPV powder requires proper reconstitution under sterile laboratory conditions using appropriate solvents based on the planned experimental assay. KPV is highly water-soluble due to its polar lysyl residue.

1. Reconstitution Medium: Dissolve lyophilized KPV in sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4). 2. Solubilization: Gently swirl or invert the vial. Avoid aggressive vortexing or sonic agitation to prevent peptide shear. 3. Concentration Calibration: Prepare concentrated stock solutions (e.g., 1 mg/mL or 5 mg/mL) to allow precise volumetric pipetting into working culture media. 4. Aliquoting: Divide stock solutions into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles, which degrade peptide bond stability.

Storage, Stability, and Handling Parameters

Lyophilized KPV should be stored at -20°C upon receipt for short-to-medium term storage, or at -80°C for long-term preservation exceeding 12 months. Keep lyophilized vials protected from light exposure.

Once reconstituted in liquid solution, KPV stock aliquots remain stable at 4°C for up to 7–10 days. For extended storage of reconstituted solutions, keep aliquots frozen at -20°C or -80°C for up to 3 months. Avoid frost-free freezers due to temperature fluctuations during automatic defrost cycles.

Procuring KPV for Institutional and Laboratory Accounts

PX1 Research provides direct fulfillment for university laboratories, private biotechnology firms, and contract research organizations (CROs). For high-throughput screening or bulk preclinical study requirements, institutional buyers can establish a dedicated account through our wholesale peptide program.

All orders ship directly from our state-of-the-art dispatch facilities located in California and Arizona. Orders placed Monday through Friday before 2:00 PM PST feature same-day processing to ensure rapid, secure delivery of temperature-sensitive research compounds.